[Alport syndrome: Pathogenesis, pathophysiology, and therapy].
Tokura
Takehiko
T
Division of Nephrology, Department of Internal Medicine, Kawasaki Medical School.
Sasaki
Tamaki
T
Kashihara
Naoki
N
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D024141:Collagen Type IV / Q000235:genetics; D018753:Diet, Protein-Restricted; D004039:Diet, Sodium-Restricted; D050533:Glomerular Basement Membrane / Q000473:pathology; D006801:Humans; D009154:Mutation; D009394:Nephritis, Hereditary / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; C478159:COL4A5 protein, human; D024141:Collagen Type IV